GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
C

Capricor Therapeutics CAPR · USD

Health Care · US listing · 🇺🇸 United States

Compare

9.85

+9.44%

Close of 9 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in USD, from our data supplier.

FY2025

Revenue

—

FY2016FY2025

Net income

−$105.0m

FY2016FY2025

Free cash flow

−$72.7m

FY2016FY2025

Shareholders' equity

$305.8m

FY2016FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue—$22.3m$25.2m$2.6m$244,898$310,250$1.0m$1.7m$1.4m$3.2m
Research and development$84.5m$50.0m$36.4m$21.8m$13.6m$8.5m$5.1m$12.1m$10.8m$16.0m
Operating income−$108.1m−$42.6m−$24.1m−$29.7m−$20.9m−$13.7m−$7.7m−$15.3m−$12.9m−$18.5m
Net income−$105.0m−$40.5m−$22.3m−$29.0m−$20.0m−$13.7m−$7.6m−$15.2m$2.4m−$18.8m
Diluted earnings per share-2.15-1.15-0.83-1.15-0.83-0.67-1.76-4.890.83-8.79

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Total assets$355.9m$170.5m$58.7m$50.1m$41.3m$34.6m$11.1m$9.2m$16.3m$18.7m
Cash and short-term investments$318.1m$151.5m$39.5m$41.4m$34.9m$32.7m$9.9m$7.3m$14.1m$16.2m
Total liabilities$50.2m$25.0m$36.1m$38.3m$10.0m$6.4m$4.3m$4.6m$5.0m$22.8m
Debt$3.6m$3.4m$3.4m$3.4m$3.4m$3.7m$3.4m$3.4m$3.4m$17.0m
Shareholders' equity$305.8m$145.5m$22.6m$11.8m$31.4m$28.2m$6.8m$4.6m$11.2m−$4.0m
Shares outstanding49m35m27m25m24m20m4m3m3m2m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations−$69.8m−$40.0m−$25.6m$4.9m−$16.8m−$10.1m−$6.8m−$13.9m−$14.2m−$15.8m
Capital spending−$2.9m−$1.5m−$2.0m−$3.4m−$1.2m−$547,601−$547,601−$316,486−$32,185−$193,739
Free cash flow−$72.7m−$41.5m−$27.6m$1.6m−$18.0m−$10.6m−$7.4m−$14.2m−$14.3m−$16.0m

Latest quarters

By quarter end

Jun 2026Mar 2026Dec 2025Sept 2025Jun 2025Mar 2025Dec 2024Sept 2024
Revenue——————$11.1m$2.3m
Operating income−$42.9m−$36.8m−$29.2m−$26.3m−$27.7m−$25.0m−$7.7m−$13.0m
Net income−$40.73bn−$33.9m−$30.2m−$24.6m−$25.9m−$24.4m−$7.1m−$12.6m
Diluted earnings per share-703.20-0.59-0.62-0.50-0.53-0.50-0.20-0.36
Cash from operations—−$29.0m−$23.0m−$19.0m−$20.0m−$6.0m−$14.0m−$11.0m
Capital spending—−$10.0m−$5.0m−$4.0m−$1.0m−$1.0m——
Free cash flow—−$39.0m−$28.0m−$23.0m−$21.0m−$7.0m——
Total assets$368.7m$326.3m$355.9m$126.4m$133.6m$153.8m$170.5m$93.0m
Cash and short-term investments$237.9m$278.6m$318.1m$98.6m$122.8m$144.8m$151.5m$85.0m
Debt$1.5m$7.2m$3.6m$3.5m$4.2m$842,101$834,799$813,634
Shareholders' equity$246.2m$278.7m$305.8m$83.9m$105.0m$127.6m$145.5m$68.3m

Financial ratios

Data as of 4 Nov 2026

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2017FY2016FY2015
Operating margin—-181.7%-88.5%-1137.4%-8175.9%-4412.6%-769.5%———
Net margin—-181.7%-88.5%-1137.4%-8175.9%-4401.9%-760.4%———
Return on equity-34.4%-27.8%-98.6%-246.2%-63.8%-48.4%————
Return on assets-29.5%-23.7%-37.9%-57.9%-48.4%-39.4%————
Free cash flow yield-16.6%-13.3%-10.7%4.0%-7.8%-5.7%————
Revenue growth—-11.5%886.8%941.8%-21.1%-69.1%-39.9%———
Earnings growth159.6%81.6%-23.2%44.9%46.6%78.7%————
Current ratio9.01x7.77x1.63x1.82x8.82x11.33x————
Debt to equity0.01x0.01x0.03x0.34x0.12x0.01x————
Equity ratio85.9%85.3%38.5%23.5%75.9%81.5%————
Interest coverage-33.49x——-17.09x-19.29x——-32.25x-49.26x-50.73x
R&D as a share of sales—224.4%144.8%855.1%5541.5%2725.9%511.6%———
Buybacks as a share of market value-38.7%-31.5%-6.4%-4.2%-18.5%-369.7%————

Growth per year

Compound annual rate

3 years5 years10 years
Operating income53.8%51.2%24.0%
Net income53.5%50.4%23.4%

Valuation history

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Price to earnings-2.7-2.5-1.2-0.4-0.4-0.6-0.1-0.12.3-0.1
Price to sales—4.51.14.634.627.00.70.94.10.8

Market value over time

30 Dec 2016 to 3 Nov 2026, in USD

$53.2m$477.3m

Share price return

Finished calendar years

2025202420232022202120202019201820172016
Return109%196%109%7%-19%281%-80%-66%59%-15%

Dividends and splits

Per share, in the currency the company pays

Paid for 0 years.

  • 10-to-1 reverse split · 5 Jun 2019
  • 50-to-1 reverse split · 21 Nov 2013
  • 10-to-1 reverse split · 9 Feb 2007

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.